A Randomized, 24 Week, Active-controlled, Open-label, 3-arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of iGlarLixi to Insulin Glargine and Lixisenatide in Type 2 Diabetes Mellitus Patients Insufficiently Controlled With Oral Antidiabetic Drug(s)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008820/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objectives:
The co-primary objective of this study is:
- To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine
and lixisenatide) versus lixisenatide on glycemic control as assessed by glycated
hemoglobin A1c (HbA1c) change.
- To demonstrate the non-inferiority of iGlarLixi versus insulin glargine on glycemic
control as assessed by HbA1c change.
Secondary Objectives:
- To assess the effects of iGlarLixi in comparison with insulin glargine alone and
lixisenatide alone.
- To assess the safety in each treatment group.
提供机构：
Vivli
创建时间：
2023-02-27
